Arkolith/Insider Trading/SUPN/Form 4

Khattar Jack A.

President, CEO, DirectorSUPERNUS PHARMACEUTICALS, INC. (SUPN) · full profile →Form 4 · filed Mar 10, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)39K—$01.2M
Mar 6, 2026Tax withholding(F)17K$54.73$907K1.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)39K—$00

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001539937-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML